Robert W. Baird analyst Brian Skorney maintained a Sell rating on Biogen (NASDAQ:BIIB) on Monday, setting a price target of $216, which is approximately 16.96% below the present share price of $260.13.
Skorney expects Biogen to post earnings per share (EPS) of $2.33 for the first quarter of 2021.
The current consensus among 22 TipRanks analysts is for a Moderate Buy rating of shares in Biogen, with an average price target of $307.42.
The analysts price targets range from a high of $458 to a low of $200.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $2.85 billion and a net profit of -$485.9 million. The company's market cap is $39.63 billion.
According to TipRanks.com, Robert W. Baird analyst Brian Skorney is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.2% and a 53.40% success rate.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp (OTC:SHCAY) in 1978 and is headquartered in Cambridge, MA.